Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Completed · Phase 1 · Has a placebo group
Conditions studied: Systemic Juvenile Idiopathic Arthritis
In brief
This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.
Key facts
- Study ID
- NCT01803321
- Run by
- Regeneron Pharmaceuticals
- People needed
- 24
- Starts
- 2005-11-01
- Expected to finish
- 2008-06-01
- Last updated by the study team
- 2013-03-04
Who can join
Age: 4 and older, up to 20. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Los Angeles, California, United States
- Study site — Wilmington, Delaware, United States
- Study site — Chicago, Illinois, United States
- Study site — Hackensack, New Jersey, United States
- Study site — Long Island City, New York, United States
- Study site — Cincinnati, Ohio, United States
- Study site — Cleveland, Ohio, United States
- Study site — Dallas, Texas, United States
- Study site — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.